Evommune (EVMN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
2 Jun, 2026Opening remarks and agenda
Meeting commenced at 11:30 A.M. ET on June 2, 2026, via a virtual platform, with recording available for 30 days.
Board members, executive officers, auditors, and legal counsel were introduced at the start.
The agenda included two proposals: election of directors and ratification of the independent auditor.
Shareholder proposals
Two proposals were presented: election of two Class 1 directors to serve until 2029, and ratification of BDO USA, P.C. as independent auditor for fiscal year ending December 31, 2026.
Q&A with stakeholders
Shareholders could submit questions online during the meeting, but no questions were received.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Evommune
- Advancing novel oral and biologic therapies for inflammation with strong clinical and financial momentum.EVMN
Corporate presentation8 May 2026 - Net loss widened to $21.7 million in Q1 2026, with cash runway extended through 2028.EVMN
Q1 20268 May 2026 - Director elections and auditor ratification headline the June 2026 virtual annual meeting.EVMN
Proxy filing21 Apr 2026 - Shareholders will vote on director elections and auditor ratification, with strong governance and ESG oversight.EVMN
Proxy filing21 Apr 2026 - Biotech enables resale of 4.5M shares post-IPO, advancing inflammation therapies amid sector risks.EVMN
Registration filing17 Apr 2026 - EVO756 phase IIb trial targets migraine prevention with a novel oral MRGPRX2 antagonist.EVMN
Status update13 Apr 2026 - EVO301 showed rapid, significant efficacy and safety in phase 2A atopic dermatitis, enabling phase 2B plans.EVMN
Study result12 Apr 2026 - Advancing novel oral and biologic therapies for inflammation with key data expected in 2026.EVMN
Corporate presentation7 Apr 2026 - Strong clinical progress and $125M financing extend cash runway through 2028.EVMN
Q4 20256 Mar 2026